Team of oncology experts expand data in Tumor Model Compendium and
present strong portfolio at industry conferences
WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 13, 2018--
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced new additions to the Tumor
Model Compendium. Charles River’s Compendium provides access to a
comprehensive collection of well-established tumor models for
early-stage oncology research.
The most recent Compendium update adds gastric and liver models, as well
as new molecular data for leukemia, liver cancer, lymphoma, breast
cancer and ovarian cancer. The newest additions to the Compendium
provide oncology researchers access to data that allows them to identify
the most appropriate tumor models, leading to a more targeted study
design from the start, saving time and money on the path to the clinic.
The Compendium includes tumor models from a wide range of tumor subtypes
for both in vivo and in vitro oncology research, including patient-derived
xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic
Presence at Scientific Conferences
The Compendium is just one example of Charles River’s commitment to
oncology research. Charles River experts presented four posters at the
Society for Immunotherapy’s (SITC) 33rd Annual Meeting and
will present nine posters at the European Organisation for Research and
Treatment of Cancer (EORTC) Conference in Dublin, Ireland.
Noteworthy posters include:
Modulation of adenosine levels in the tumor microenvironment
following treatment with anti-PD1 antibodies and oxaliplatin: an in
vivo microdialysis study (Presented at SITC’s 33rd
Annual Meeting by Arash Rassoulpour) Utilizing in vivo microdialysis,
a technique that has been prominent in neuroscience research for over
50 years, Charles River researchers monitored oncometabolites and
immunomodulators directly in the tumor microenvironment.
Development of a disseminated AML mouse model to evaluate the
therapeutic activity of immune checkpoint inhibitors using
bioluminescence imaging (To be presented at EORTC by David
Harris) Charles River researchers developed a disseminated AML
disease model to evaluate the therapeutic response to immune
checkpoint inhibitors, PD-1, PD-L1 and CTLA-4.
A full schedule of Charles River’s activities during SITC’s
33rd Annual Meeting and EORTC
is available online, with poster reprint available after the
conferences. Reprints of posters presented at EORTC will also be
available in booth A2 during the show.
“The power of our oncology portfolio is stronger than ever. Our
scientists have worked diligently to accelerate cancer research and
anticancer drug development efforts so patients can get the treatments
they desperately need.” –Birgit Girshick, Corporate Executive Vice
President, Discovery and Safety Assessment, Charles River
“Since its inception, our Tumor Model Compendium has made finding the
best research model for oncology research easier. We are excited about
the latest additions and are proud to offer this important resource to
oncology researchers.” –Julia Schueler, Research Director, Charles
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their research
and drug development efforts. Our dedicated employees are focused on
providing clients with exactly what they need to improve and expedite
the discovery, early-stage development and safe manufacture of new
therapies for the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181113005164/en/
Source: Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc.
Corporate Vice President, Investor Relations
Amy Cianciaruso, 781-222-6168
President, Public Relations